Skip to content

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)

Longevity medicationsdrugEarly stage

Availability Prescription, repurposed

What it is

SGLT2 inhibitors are diabetes drugs that block a kidney transporter, so glucose leaves in the urine instead of returning to the blood. The class includes empagliflozin, dapagliflozin, and canagliflozin. Their cardiovascular and kidney results were large enough that use spread well beyond diabetes.

Why people take it

The outcome data is the draw. Few drugs in any category have moved death rates in randomized trials, and this class did, in people who were not selected for aging research. Longevity users want the metabolic and cardiorenal protection, plus modest weight and blood pressure effects, and one animal lifespan signal behind it.

How it's delivered

A once-daily oral tablet, taken indefinitely. Prescribers watch kidney function and volume status. Known risks include genital yeast infections, urinary tract infections, dehydration, and a rare ketoacidosis that can occur at normal blood glucose, which makes it easy to miss.

Where the evidence stands

EMPA-REG OUTCOME found empagliflozin cut cardiovascular death by 38 percent and all-cause death by 32 percent in high-risk diabetes. DAPA-HF extended the benefit to heart failure patients without diabetes. In mice, canagliflozin raised male median lifespan 14 percent with no effect in females, one of the sharper sex splits in the field. Canagliflozin also roughly doubled amputations in its own outcome trial, drawing an FDA boxed warning in 2017 that was removed in 2020 while the risk stayed on the label.

Estimated cost

  • $500–$700/mobrand, before coupons or insurance
  • Generic dapagliflozin materially cheaper where stocked
  • $99–$249/motelehealth membership on top, in some programs
  • Prescription required
  • Covered for diabetes, heart failure, and kidney disease, not for aging

Who offers it

  • TelehealthHealthspan
  • Telehealthgeneral Rx platforms
  • ProtocolBlueprint
How we know

Observed in provider menus on our last research pass; each listing is stamped when verified. We may be compensated when you contact providers through Longevity.io; payment never affects ranking.

Go deeper

No guide for this class yet. The medications and supplements hub covers the repurposed-drug set, and how outcome trials differ from aging claims.

Explore medications and supplements

Longevity.io is for educational purposes only and is not medical advice. Whether an SGLT2 inhibitor belongs in a plan is a conversation for a clinician who knows kidney function, medications, and history. Confirm eligibility, services, and pricing directly with any provider.

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint